Peninsula biotech scores $80M upfront in potential $1.6 billion cancer drug deal
March 24, 2020 at 17:35 PM EDT
The South San Francisco company's technology is designed to mask a drug until it lands on a cancer cell, where it then is unmasked and spills out its payload to destroy the cell with minimal damage to surrounding healthy tissue.